Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.
Surgeons from NYU Langone Health hit a major milestone in transplantation science after successfully attaching a pig’s kidney to a human patient and watching it work for several hours.
The U.S. Food and Drug Administration approved Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies (SPAC) that will be focused on taking biotech companies public.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes the use of miniature lungs and colons to help test Covid-19 treatments.
More than half of Covid-19 patients discharged from hospitals still experienced symptoms of breathlessness, fatigue, anxiety and depression for two to three months after their initial infection, according to the findings of a small UK study.
The U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.
A study published in the scientific journal Nature explains why certain kinds of cancer cells often spread to the lymph nodes before various organs within the body.
The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s Ultomiris for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients.
Deep Genomics’ proprietary artificial intelligence-based drug discovery platform identified a novel treatment target and corresponding drug candidate for the rare and potentially life-threatening genetic disorder Wilson disease.
